CA3188250A1 - Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor - Google Patents
Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitorInfo
- Publication number
- CA3188250A1 CA3188250A1 CA3188250A CA3188250A CA3188250A1 CA 3188250 A1 CA3188250 A1 CA 3188250A1 CA 3188250 A CA3188250 A CA 3188250A CA 3188250 A CA3188250 A CA 3188250A CA 3188250 A1 CA3188250 A1 CA 3188250A1
- Authority
- CA
- Canada
- Prior art keywords
- crystalline
- anhydrate
- compound
- powder diffraction
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063060281P | 2020-08-03 | 2020-08-03 | |
| US63/060,281 | 2020-08-03 | ||
| PCT/US2021/044341 WO2022031701A1 (en) | 2020-08-03 | 2021-08-03 | Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3188250A1 true CA3188250A1 (en) | 2022-02-10 |
Family
ID=77640732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3188250A Pending CA3188250A1 (en) | 2020-08-03 | 2021-08-03 | Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230286972A1 (https=) |
| EP (1) | EP4188925A1 (https=) |
| JP (1) | JP7789056B2 (https=) |
| KR (1) | KR20230061395A (https=) |
| CN (1) | CN116917284A (https=) |
| AR (1) | AR123132A1 (https=) |
| AU (1) | AU2021322186A1 (https=) |
| BR (1) | BR112023002013A2 (https=) |
| CA (1) | CA3188250A1 (https=) |
| CL (1) | CL2023000327A1 (https=) |
| CO (1) | CO2023002543A2 (https=) |
| CR (1) | CR20230118A (https=) |
| IL (1) | IL300365A (https=) |
| MX (1) | MX2023001469A (https=) |
| PE (1) | PE20231168A1 (https=) |
| TW (1) | TW202220984A (https=) |
| UY (1) | UY39366A (https=) |
| WO (1) | WO2022031701A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2602139B (en) * | 2020-12-18 | 2024-07-24 | Nexeon Ltd | Electroactive materials for metal-ion batteries |
| WO2025184490A1 (en) | 2024-03-01 | 2025-09-04 | Biogen Ma Inc. | N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2780014A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3555087A1 (en) | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Monocyclic oga inhibitor compounds |
| TWI654978B (zh) | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| WO2018154133A1 (en) | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
| US12180205B2 (en) * | 2018-09-19 | 2024-12-31 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
-
2021
- 2021-08-03 WO PCT/US2021/044341 patent/WO2022031701A1/en not_active Ceased
- 2021-08-03 PE PE2023000189A patent/PE20231168A1/es unknown
- 2021-08-03 TW TW110128540A patent/TW202220984A/zh unknown
- 2021-08-03 KR KR1020237007569A patent/KR20230061395A/ko active Pending
- 2021-08-03 CN CN202180066901.9A patent/CN116917284A/zh active Pending
- 2021-08-03 IL IL300365A patent/IL300365A/en unknown
- 2021-08-03 JP JP2023507579A patent/JP7789056B2/ja active Active
- 2021-08-03 BR BR112023002013A patent/BR112023002013A2/pt not_active Application Discontinuation
- 2021-08-03 AU AU2021322186A patent/AU2021322186A1/en active Pending
- 2021-08-03 EP EP21766024.0A patent/EP4188925A1/en active Pending
- 2021-08-03 AR ARP210102157A patent/AR123132A1/es unknown
- 2021-08-03 UY UY0001039366A patent/UY39366A/es unknown
- 2021-08-03 MX MX2023001469A patent/MX2023001469A/es unknown
- 2021-08-03 US US18/019,270 patent/US20230286972A1/en active Pending
- 2021-08-03 CA CA3188250A patent/CA3188250A1/en active Pending
- 2021-08-03 CR CR20230118A patent/CR20230118A/es unknown
-
2023
- 2023-02-01 CL CL2023000327A patent/CL2023000327A1/es unknown
- 2023-03-01 CO CONC2023/0002543A patent/CO2023002543A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202220984A (zh) | 2022-06-01 |
| CN116917284A (zh) | 2023-10-20 |
| PE20231168A1 (es) | 2023-07-26 |
| US20230286972A1 (en) | 2023-09-14 |
| AU2021322186A1 (en) | 2023-04-06 |
| BR112023002013A2 (pt) | 2023-05-02 |
| MX2023001469A (es) | 2023-06-16 |
| EP4188925A1 (en) | 2023-06-07 |
| CR20230118A (es) | 2023-06-02 |
| CO2023002543A2 (es) | 2023-06-09 |
| JP7789056B2 (ja) | 2025-12-19 |
| UY39366A (es) | 2022-02-25 |
| CL2023000327A1 (es) | 2023-10-06 |
| JP2023536911A (ja) | 2023-08-30 |
| IL300365A (en) | 2023-04-01 |
| WO2022031701A1 (en) | 2022-02-10 |
| AR123132A1 (es) | 2022-11-02 |
| KR20230061395A (ko) | 2023-05-08 |
| WO2022031701A9 (en) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10081625B2 (en) | 5-methyl-1,2,4-oxadiazol-3-yl compounds | |
| EP3630755B1 (en) | 5-methyl-1,3,4-oxadiazol-2-yl compounds | |
| JP2018522032A (ja) | ムスカリンアゴニスト | |
| JP2017095501A (ja) | ムスカリンｍ１受容体アゴニスト | |
| US10537569B2 (en) | Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same | |
| KR20230145313A (ko) | Bcl의 결정성 고체 메글루민 염 억제제 및 이의 제조 방법 및 이의 사용 방법 | |
| CA3188250A1 (en) | Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor | |
| TW201742866A (zh) | 一種腎外髓質分泌鉀通道抑制劑的可藥用鹽 | |
| US7335380B2 (en) | Amlodipine free base | |
| EA049044B1 (ru) | Кристаллические формы ингибитора о-гликопротеин-2-ацетамидо-2-дезокси-3-d-глюкопиранозидазы | |
| EP3571195A1 (en) | A free base oxazine derivative in crystalline form | |
| KR20030027119A (ko) | 1,3,4-옥사디아졸 유도체의 신규 결정, 그 제조 방법 및그것을 유효 성분으로서 함유하는 약제 | |
| CA3108158C (en) | 5-methyl-4-fluoro-thiazol-2-yl compounds | |
| WO2025137366A2 (en) | Solid-state forms of stat3 inhibitors and methods of use thereof | |
| NZ754849B2 (en) | N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor | |
| HK1251559A1 (zh) | 普那布林組合物 | |
| SI21121A (sl) | Prosta baza amlodipina | |
| JP2010526789A (ja) | Ｆｘａインヒビターの新規固形形態 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241217 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241217 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250723 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251031 |